Treatment Challenges in Squamous NSCLC

In this segment, the panel examines why therapeutic advances in squamous non-small cell lung cancer (NSCLC) have not matched the pace of progress seen in nonsquamous disease. Dr. Edward Kim discusses the historical development of targeted therapies in lung cancer and explains how the limited number of actionable and druggable alterations in squamous NSCLC has complicated efforts to develop effective targeted treatments. The panel references the Lung-MAP experience and other biomarker-directed approaches, noting that these efforts have not yet produced the same degree of therapeutic progress seen in other NSCLC subtypes. The experts also discuss the biological complexity of squamous NSCLC, including its association with smoking and frequent TP53 alterations, and the challenges these features present for drug development. The discussion then turns to PRAGMATICA-LUNG, including the initial interest generated by earlier-phase findings and the lack of a significant overall survival benefit in the phase 3 study. Despite the efficacy result, the panel highlights lessons from the trial regarding clinical trial design and expanding trial access for patients treated in community settings.